US 11,896,565 B2
Beta-hydroxybutyrate mixed salt compositions and methods of use
Gary Millet, Salt Lake City, UT (US)
Assigned to AXCESS GLOBAL SCIENCES, LLC, Salt Lake City, UT (US)
Filed by AXCESS GLOBAL SCIENCES, LLC, Salt Lake City, UT (US)
Filed on Dec. 21, 2021, as Appl. No. 17/557,429.
Application 16/720,211 is a division of application No. 16/272,145, filed on Feb. 11, 2019, granted, now 10,736,861, issued on Aug. 11, 2020.
Application 17/557,429 is a continuation of application No. 17/198,634, filed on Mar. 11, 2021, granted, now 11,241,403.
Application 17/198,634 is a continuation of application No. 16/996,509, filed on Aug. 18, 2020, granted, now 10,973,786, issued on Apr. 13, 2021.
Application 16/996,509 is a continuation in part of application No. 16/720,211, filed on Dec. 19, 2019, granted, now 11,020,362, issued on Jun. 1, 2021.
Application 16/272,145 is a continuation in part of application No. 15/454,157, filed on Mar. 9, 2017, granted, now 10,292,952, issued on May 21, 2019.
Claims priority of provisional application 62/307,203, filed on Mar. 11, 2016.
Prior Publication US 2022/0110895 A1, Apr. 14, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/19 (2006.01); A61K 31/593 (2006.01); A23L 33/12 (2016.01); A61P 3/00 (2006.01); A61K 47/14 (2017.01); A23L 33/16 (2016.01); A23L 33/175 (2016.01); A61K 9/00 (2006.01); A61K 9/02 (2006.01); A61K 9/14 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); A61K 47/10 (2017.01)
CPC A61K 31/19 (2013.01) [A23L 33/12 (2016.08); A23L 33/16 (2016.08); A23L 33/175 (2016.08); A61K 9/006 (2013.01); A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61K 9/0095 (2013.01); A61K 9/02 (2013.01); A61K 9/14 (2013.01); A61K 9/145 (2013.01); A61K 9/2004 (2013.01); A61K 9/2013 (2013.01); A61K 9/4841 (2013.01); A61K 9/4858 (2013.01); A61K 47/10 (2013.01); A61K 47/14 (2013.01); A61P 3/00 (2018.01); A23V 2002/00 (2013.01); A23V 2200/30 (2013.01); A23V 2250/02 (2013.01); A23V 2250/1876 (2013.01); A23V 2250/1878 (2013.01); A23V 2250/1884 (2013.01)] 23 Claims
 
1. A composition for increasing ketone level in a subject, comprising:
a plurality of beta-hydroxybutyrate salts comprised of:
at least one beta-hydroxybutyrate salt selected from:
calcium beta-hydroxybutyrate; and
magnesium beta-hydroxybutyrate; and
at least one other beta-hydroxybutyrate salt selected from:
sodium beta-hydroxybutyrate;
potassium beta-hydroxybutyrate;
calcium beta-hydroxybutyrate; and
magnesium beta-hydroxybutyrate; and
at least one additional ketone body or ketone precursor selected from the group consisting of acetoacetate, ketone ester, amino acid salt of beta-hydroxybutyrate, and other ketone body or ketone precursor that causes a rise in blood ketone level without adding more electrolytes to the subject's bloodstream,
wherein the composition is free of medium chain fatty acids having 6 to 12 carbons and glycerides or other esters thereof.